Skip to main content
OpenTrials
Completed

NCT Number: NCT00916149

Cognitive Effects of Treatment of Interictal Discharges

The purpose of this study is to determine if levetiracetam (for patients with focal seizures) or lamotrigine (for patients with generalized seizures) reduces the occurrence of interictal discharges. The study investigates the possible correlation between reduction of interictal discharges and improved cognitive performance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

About this study

Subjects with seizures will be studied with electroencephalography (EEG) and offered medication for prevention of recurrent seizures. Those with focal seizures will be treated with levetiracetam, and those with generalized seizures will be treated with lamotrigine. Subjects will undergo repeated EEG with concurrent cognitive testing before and after initiation of treatment. The proposed study tests 3 hypotheses: 1. that treatment with levetiracetam will reduce focal interictal epileptiform activity, 2. that treatment with lamotrigine will reduce generalized interictal epileptiform activity, and 3. that the extent of interictal epileptiform activity is inversely associated with performance on neuropsychological batteries and computerized cognitive testing. Repeated cognitive/neuropsychological testing obtained at steady state of the study drug and again after approximately 2 months on the final dosage will serve to evaluate the timecourse of potential cognitive benefits.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-55 years of age
  • Normal Intelligence Quotient (IQ ≥ 80) as estimated by the Wechsler Test of Adult Reading (WTAR)
  • Able to give consent
  • The subject's treating physician is planning to prescribe levetiracetam for focal or lamotrigine for generalized seizure prevention
  • Either symptomatic or idiopathic seizures.

Exclusion criteria

  • Non-native English speaking and/or multilingual
  • Frequent seizures, since seizures themselves impair cognitive function and present a confounding variable. Subjects may have no more than one seizure or one cluster of seizures per month, with a cluster of seizures including more than one seizure, but between which the patient returns to baseline. The cluster may occur over no more than two consecutive days in one month.
  • Seizure(s) must not have occurred within 3 days of enrollment and testing.
  • Those with focal seizures who have evidence of renal disease (creatinine clearance less than 80) will be excluded from participation, as levetiracetam is cleared by the kidney.
  • Those with focal seizures who have neutrophil counts <1000/microliter will be excluded from participation, as levetiracetam may lower white blood cell counts.
  • Those with focal seizures and irritability or mood swings will not be eligible for participation, as levetiracetam may exacerbate these symptoms. This will be determined by self-report, information obtained from the referring physician and medical record.
  • Those with generalized seizures who have moderate to severe liver dysfunction (Child-Pugh Grades B and C) will be excluded from participation, as lamotrigine is cleared by the liver and the proposed dosing may not be tolerable in this population. This will be determined by self-report, information obtained from the referring physician, a comprehensive metabolic panel (routinely obtained in new-onset seizures) and the medical record.
  • Subjects who are pregnant will not be eligible to take part in the study, as levetiracetam and lamotrigine are classified as Pregnancy Category C drugs and may pose risk to the fetus. Women of childbearing potential will have a urine pregnancy test prior to participation in the study. The urine pregnancy test will be repeated at the final study visit. Subjects with epilepsy who are of childbearing potential must use acceptable methods of birth control during the study, to be continued until one month after discontinuation of the study drug. If a subject does become pregnant during this time period, she must notify the investigators.
  • Women who are breastfeeding may not participate in this study. Levetiracetam and lamotrigine may pass into the breastmilk of nursing mothers, posing a risk to the baby.
  • Hypersensitivity to lamotrigine, levetiracetam or any components of these products

Treatment and study plan

Levetiracetam

Drug

The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.

Other names: Keppra

Lamotrigine

Drug

The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:

The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study.

Other names: Lamictal

Primary outcomes

  1. Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment

    Time frame: 1 and 11 weeks

    This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls.

Secondary outcomes

  1. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Trial 1 Learning Score

    Time frame: 1 and 11 weeks

    Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory)

  2. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Total Learning

    Time frame: 1 and 11 weeks

    Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled.

  3. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Short Delay

    Time frame: 1 and 11 weeks

    Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled)

  4. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Long Delay

    Time frame: 1 and 11 weeks

    Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled)

  5. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Learning

    Time frame: 1 and 11 weeks

    Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial)

  6. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Total Learning

    Time frame: 1 and 11 weeks

    Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled)

  7. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Delayed Recall

    Time frame: 1 and 11 weeks

    Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay)

  8. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: QOLIE

    Time frame: 1 and 11 weeks

    Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life)

  9. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: LNS

    Time frame: 1 and 11 weeks

    Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence.

  10. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Spatial Span

    Time frame: 1 and 11 Weeks

    Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards.

  11. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Span

    Time frame: 1 and 11 weeks

    Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards.

  12. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Fluency

    Time frame: 1 and 11 weeks

    Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.)

  13. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Stroop

    Time frame: 1 and 11 weeks

    Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.)

  14. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Design Fluency

    Time frame: 1 and 11 weeks

    Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.)

  15. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Trails Test

    Time frame: 1 and 11 weeks

    Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.)

  16. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Grooved Pegboard

    Time frame: 1 and 11 weeks

    Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.)

  17. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Symbol

    Time frame: 1 and 11 weeks

    Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.)

  18. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Accuracy

    Time frame: 1 and 11 weeks

    Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct)

  19. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Reaction Time (CPT RT)

    Time frame: 1 and 11 weeks

    Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance)

  20. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Accuracy

    Time frame: 1 and 11 weeks

    Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%)

  21. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Reaction Time

    Time frame: 1 and 11 weeks

    Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance)

  22. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Accuracy

    Time frame: 1 and 11 weeks

    Change in Verbal Working Memory Accuracy Score (range 0-100%)

  23. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Reaction Time

    Time frame: 1 and 11 weeks

    Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed)

  24. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Accuracy

    Time frame: 1 and 11 weeks

    Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%)

  25. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Reaction Time

    Time frame: 1 and 11 weeks

    Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds)

  26. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Accuracy

    Time frame: 1 and 11 weeks

    Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%)

  27. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Reaction Time

    Time frame: 1 and 11 weeks

    Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)

  28. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Accuracy

    Time frame: 1 and 11 weeks

    Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%)

  29. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Reaction Time

    Time frame: 1 and 11 weeks

    Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)

  30. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: NDDIE

    Time frame: 1 and 11 weeks

    Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms)

  31. Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Adverse Events Profile (AEP)

    Time frame: 1 and 11 weeks

    Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects)

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • GlaxoSmithKline
  • National EpiFellows Foundation
  • UCB Pharma
  • UCB Young Investigator Research Program

Registry information

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
Jun 9, 2009
Registry last updated
Oct 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.